Business Context and Reporting Period
Company: Smith & Nephew plc (LSE: SN, NYSE: SNN)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: September 16, 2026
Business Overview: A global medical technology company focused on Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company operates in approximately 100 countries and reported annual sales of $6.2 billion in 2025.
Key Financial Metrics and Transaction Details
This filing details a specific debt management transaction rather than a full financial report. Key metrics related to the transaction include:
- Security: 2.032% Senior Notes due 2030 (CUSIP: 83192P AA6).
- Outstanding Principal: $900,000,000.
- Tender Offer Size: Up to $250,000,000 aggregate principal amount.
- Tender Offer Consideration: $878.90 per $1,000 principal amount (excluding accrued interest).
- Reference Yield: 4.833% (based on 4.375% U.S. Treasury due August 31, 2031, plus a 55 basis point fixed spread).
- Settlement Date: Expected September 18, 2026.
Note: The filing does not provide current period revenue, profit, cash flow, or liquidity metrics beyond the 2025 annual sales figure mentioned in the company overview.
Material Changes and Transaction Mechanics
The primary material event is the pricing of a cash tender offer to repurchase a portion of the company's outstanding debt. Key mechanics include:
- Expiration: The offer expired at 5:00 p.m. New York City time on September 15, 2026.
- Proration: If the amount tendered exceeds the $250 million maximum, acceptance will be prorated among holders.
- Conditions: The offer is subject to conditions, including a Financing Condition, which the company states has been satisfied.
- Interest: Accepted notes will receive accrued and unpaid interest from the last payment date up to, but excluding, the settlement date.
Outlook, Risks, and Management Commentary
Management Commentary: The company expects to announce the results of the tender offer on September 16, 2026. The company reserves the right to purchase additional notes in the open market or through other means in the future, though no assurance is given regarding future actions.
Risks and Contingencies: The filing includes a comprehensive list of forward-looking statement risks, including:
- Geopolitical conflicts in Europe and the Middle East.
- Economic conditions affecting healthcare providers and payers.
- Regulatory approvals, reimbursement decisions, and government actions.
- Product defects, recalls, and quality management compliance.
- Supply chain disruptions and cybersecurity threats.
- Foreign exchange volatility and changes in taxation regulations.
Investor Verification Checklist
- Verify the final results of the tender offer (total amount tendered vs. accepted) once announced by the company.
- Confirm the exact settlement date and payment of accrued interest for accepted notes.
- Review the full "Offer to Purchase" document for detailed terms, conditions, and withdrawal procedures.
- Monitor future filings for updates on the company's debt reduction strategy and potential open market purchases.
- Check the most recent Form 20-F (year ended Dec 31, 2025) and interim Form 6-K (six months ended June 27, 2026) for comprehensive financial performance data not included in this specific filing.